{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:19Z","timestamp":1793422639492,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["A-85B"],"award-info":[{"award-number":["A-85B"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["20233913"],"award-info":[{"award-number":["20233913"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims\/hypothesis<\/jats:title>\n                <jats:p>Immunomodulators blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have improved the treatment of a broad spectrum of cancers. These immune checkpoint inhibitors (ICIs) reactivate the immune system against tumour cells but can also trigger autoimmune side effects, including type 1 diabetes. Mesenchymal stem cell (MSC) therapy is the most prevalent cell therapy, with tissue-regenerating, anti-fibrosis and immunomodulatory functions provided by the secretome of the cells. Here, we examined whether systemic MSC treatment could prevent the development of type 1 diabetes in a NOD mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The purified PD-L1 monoclonal antibody was administered to induce diabetes in male NOD mice which normally do not develop diabetes. Human adipose-derived MSCs were administered by tail vein injections. T cells, macrophages and monocyte-derived macrophages expressing C-X-C motif chemokine ligand 9 (CXCL9) in pancreatic sections of NOD mice and a cancer patient who developed diabetes following the ICI treatments were analysed by immunofluorescence. Tissue localisation of the injected MSCs, plasma exosome levels and plasma cytokine profiles were also investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PD-1\/PD-L1 blockade induced diabetes in 16 of 25 (64%) NOD mice which received anti-PD-L1 mAb without hMSCs [MSC(\u2212)], whereas MSC administration decreased the incidence to four of 21 (19%) NOD mice which received anti-PD-L1 mAb and hMSCs [MSC(+)]. The PD-1\/PD-L1 blockade significantly increased the area of CD3-positive T cells (6.2-fold) and macrophage-2 (Mac-2) antigen (2.5-fold)- and CXCL9 (40.3-fold)-positive macrophages in the islets. MSCs significantly reduced T cell (45%) and CXCL9-positive macrophage (67%) accumulation in the islets and the occurrence of diabetes. The insulin content (1.9-fold) and islet beta cell area (2.7-fold) were also improved by MSCs. T cells and CXCL9-positive macrophages infiltrated into the intricate gaps between the beta cells in the islets by PD-1\/PD-L1 blockade. Such immune cell infiltration was largely prevented by MSCs. The most striking difference was observed in the CXCL9-positive macrophages, which normally did not reside in the beta cell region in the islets but abundantly accumulated in this area after PD-1\/PD-L1 blockade and were prevented by MSCs. The CXCL9-positive macrophages were also observed in the islets of a cancer patient who developed diabetes following the administration of ICIs but few CXCL9-positive macrophages were observed in a control patient. Mechanistically, the injected MSCs accumulated in the lung but not in the pancreas and strongly increased plasma exosome levels and changed plasma cytokine profiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions\/interpretation<\/jats:title>\n                <jats:p>Our results suggest that MSCs can prevent the incidence of diabetes associated with immune checkpoint cancer therapy and may be worth further consideration for new adjuvant cell therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00125-022-05708-3","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T04:51:51Z","timestamp":1651726311000},"page":"1185-1197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-9214","authenticated-orcid":false,"given":"Emi","family":"Kawada-Horitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-0053","authenticated-orcid":false,"given":"Shunbun","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Tsugawa-Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sakaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"1","key":"5708_CR1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11(1):3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y","journal-title":"Nat Commun"},{"issue":"12","key":"5708_CR2","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24(12):T331\u2013T347. https:\/\/doi.org\/10.1530\/ERC-17-0358","journal-title":"Endocr Relat Cancer"},{"key":"5708_CR3","doi-asserted-by":"publisher","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC et al (2018) Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 4(2):173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","DOI":"10.1001\/jamaoncol.2017.3064"},{"issue":"8","key":"5708_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL et al (2018) Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67(8):1471\u20131480. https:\/\/doi.org\/10.2337\/dbi18-0002","journal-title":"Diabetes"},{"issue":"11","key":"5708_CR5","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M et al (2016) Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab 101(11):4431\u20134439. https:\/\/doi.org\/10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"5708_CR6","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1210\/jc.2019-00423","volume":"104","author":"VHM Tsang","year":"2019","unstructured":"Tsang VHM, McGrath RT, Clifton-Bligh RJ et al (2019) Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. J Clin Endocrinol Metab 104(11):5499\u20135506. https:\/\/doi.org\/10.1210\/jc.2019-00423","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5708_CR7","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","volume":"7","author":"A Kotwal","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7(1):e000591. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"5708_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","volume":"10","author":"MY Baden","year":"2019","unstructured":"Baden MY, Imagawa A, Abiru N et al (2019) Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10(1):58\u201366. https:\/\/doi.org\/10.1007\/s13340-018-0362-2","journal-title":"Diabetol Int"},{"issue":"1","key":"5708_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/ncpendmet0351","volume":"3","author":"T Hanafusa","year":"2007","unstructured":"Hanafusa T, Imagawa A (2007) Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3(1):36\u201345. https:\/\/doi.org\/10.1038\/ncpendmet0351","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"3","key":"5708_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/diacare.26.3.832","volume":"26","author":"MW Steffes","year":"2003","unstructured":"Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26(3):832\u2013836. https:\/\/doi.org\/10.2337\/diacare.26.3.832","journal-title":"Diabetes Care"},{"issue":"18","key":"5708_CR11","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M et al (2018) Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci 115(18):4749\u20134754. https:\/\/doi.org\/10.1073\/pnas.1718217115","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"5708_CR12","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich KJ, Yoon H, Ahmed R, Boss JM (2008) NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181(7):4832\u20134839. https:\/\/doi.org\/10.4049\/jimmunol.181.7.4832","journal-title":"J Immunol"},{"issue":"5","key":"5708_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H et al (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8(5):765\u2013772. https:\/\/doi.org\/10.1093\/intimm\/8.5.765","journal-title":"Int Immunol"},{"issue":"1","key":"5708_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26471-9","volume":"8","author":"KC Osum","year":"2018","unstructured":"Osum KC, Burrack AL, Martinov T et al (2018) Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes. Sci Rep 8(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-018-26471-9","journal-title":"Sci Rep"},{"issue":"4","key":"5708_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I et al (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883\u2013895. https:\/\/doi.org\/10.1084\/jem.20051776","journal-title":"J Exp Med"},{"issue":"1","key":"5708_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJ Ansari","year":"2003","unstructured":"Ansari MJ, Salama AD, Chitnis T et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198(1):63\u201369. https:\/\/doi.org\/10.1084\/jem.20022125","journal-title":"J Exp Med"},{"issue":"33","key":"5708_CR17","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T (2005) Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 102(33):11823\u201311828. https:\/\/doi.org\/10.1073\/pnas.0505497102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"5708_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y, Wang Y, Li Q et al (2018) Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14(8):493\u2013507. https:\/\/doi.org\/10.1038\/s41581-018-0023-5","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"5708_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1161\/CIRCRESAHA.109.210682","volume":"106","author":"I Chimenti","year":"2010","unstructured":"Chimenti I, Smith RR, Li TS et al (2010) Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 106(5):971\u2013980. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.210682","journal-title":"Circ Res"},{"issue":"10","key":"5708_CR20","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ymthe.2020.06.026","volume":"28","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Kita S, Tanaka Y et al (2020) Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice. Mol Ther 28(10):2203\u20132219. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.026","journal-title":"Mol Ther"},{"issue":"2","key":"5708_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2337\/db14-0656","volume":"64","author":"PO Carlsson","year":"2015","unstructured":"Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K (2015) Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 64(2):587\u2013592. https:\/\/doi.org\/10.2337\/db14-0656","journal-title":"Diabetes"},{"issue":"9","key":"5708_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3727\/096368913X665576","volume":"23","author":"A Bhansali","year":"2014","unstructured":"Bhansali A, Asokumar P, Walia R et al (2014) Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant 23(9):1075\u20131085. https:\/\/doi.org\/10.3727\/096368913X665576","journal-title":"Cell Transplant"},{"issue":"7","key":"5708_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00125-009-1374-z","volume":"52","author":"AM Madec","year":"2009","unstructured":"Madec AM, Mallone R, Afonso G et al (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52(7):1391\u20131399. https:\/\/doi.org\/10.1007\/s00125-009-1374-z","journal-title":"Diabetologia"},{"issue":"7","key":"5708_CR24","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","volume":"42","author":"S Yoneda","year":"2019","unstructured":"Yoneda S, Imagawa A, Hosokawa Y et al (2019) T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors. Diabetes Care 42(7):e116\u2013e118. https:\/\/doi.org\/10.2337\/dc18-2518","journal-title":"Diabetes Care"},{"issue":"10","key":"5708_CR25","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/eji.200324084","volume":"33","author":"F Tsushima","year":"2003","unstructured":"Tsushima F, Iwai H, Otsuki N et al (2003) Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol 33(10):2773\u20132782. https:\/\/doi.org\/10.1002\/eji.200324084","journal-title":"Eur J Immunol"},{"issue":"49","key":"5708_CR26","doi-asserted-by":"publisher","first-page":"31319","DOI":"10.1073\/pnas.2019743117","volume":"117","author":"H Hu","year":"2020","unstructured":"Hu H, Zakharov PN, Peterson OJ, Unanue ER (2020) Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proc Natl Acad Sci U S A 117(49):31319\u201331330. https:\/\/doi.org\/10.1073\/pnas.2019743117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5708_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","volume":"10","author":"ARR Weiss","year":"2019","unstructured":"Weiss ARR, Dahlke MH (2019) Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol 10:1191. https:\/\/doi.org\/10.3389\/fimmu.2019.01191","journal-title":"Front Immunol"},{"issue":"1","key":"5708_CR28","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.1038\/s41598-018-25700-5","volume":"8","author":"DG Leuning","year":"2018","unstructured":"Leuning DG, Beijer NRM, du Fosse NA et al (2018) The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment. Sci Rep 8(1):7716. https:\/\/doi.org\/10.1038\/s41598-018-25700-5","journal-title":"Sci Rep"},{"issue":"2","key":"5708_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J et al (2020) Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res 26(2):487\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5708_CR30","doi-asserted-by":"publisher","first-page":"e002045","DOI":"10.1136\/jitc-2020-002045","volume":"9","author":"PM Marcovecchio","year":"2021","unstructured":"Marcovecchio PM, Thomas G, Salek-Ardakani S (2021) CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer. J Immunother Cancer 9(2):e002045. https:\/\/doi.org\/10.1136\/jitc-2020-002045","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5708_CR31","doi-asserted-by":"publisher","first-page":"26238","DOI":"10.3402\/jev.v4.26238","volume":"4","author":"T Imai","year":"2015","unstructured":"Imai T, Takahashi Y, Nishikawa M et al (2015) Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles 4(1):26238. https:\/\/doi.org\/10.3402\/jev.v4.26238","journal-title":"J Extracell Vesicles"},{"issue":"2","key":"5708_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/jb\/mvaa105","volume":"169","author":"S Kita","year":"2021","unstructured":"Kita S, Shimomura I (2021) Stimulation of exosome biogenesis by adiponectin, a circulating factor secreted from adipocytes. J Biochem 169(2):173\u2013179. https:\/\/doi.org\/10.1093\/jb\/mvaa105","journal-title":"J Biochem"},{"issue":"6","key":"5708_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","volume":"7","author":"AL Perdigoto","year":"2019","unstructured":"Perdigoto AL, Quandt Z, Anderson M, Herold KC (2019) Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome. Lancet Diabetes Endocrinol 7(6):421\u2013423. https:\/\/doi.org\/10.1016\/S2213-8587(19)30072-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"5708_CR34","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V et al (2020) Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer 8(2):e001361. https:\/\/doi.org\/10.1136\/jitc-2020-001361","journal-title":"J Immunother Cancer"},{"key":"5708_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","volume":"142","author":"S Buti","year":"2021","unstructured":"Buti S, Bersanelli M, Perrone F et al (2021) Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 142:18\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.033","journal-title":"Eur J Cancer"},{"key":"5708_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fbioe.2020.00043","volume":"8","author":"A Hmadcha","year":"2020","unstructured":"Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V (2020) Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol 8:43. https:\/\/doi.org\/10.3389\/fbioe.2020.00043","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"5708_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"Liang J, Zhang H, Kong W et al (2018) Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther 9(1):312. https:\/\/doi.org\/10.1186\/s13287-018-1053-4","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"5708_CR38","doi-asserted-by":"publisher","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V (2020) Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open 3(3):e200423. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0423","journal-title":"JAMA Netw Open"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-022-05708-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05708-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T02:04:10Z","timestamp":1654653850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-022-05708-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["5708"],"URL":"https:\/\/doi.org\/10.1007\/s00125-022-05708-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"24 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}